Condition
Severe Major Depression With Psychotic Features
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
133%
4 of 3 completed with results
Key Signals
4 with results75% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 2 (1)
P 3 (1)
Trial Status
Completed3
Terminated1
Unknown1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01866098Not ApplicableCompleted
Naltrexone for Antipsychotic-Induced Weight Gain
NCT01888627Not ApplicableUnknown
Integrated Care in Psychotic Disorders With Severe Mental Illness
NCT01731119Phase 2Completed
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
NCT00637494Phase 3Terminated
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
NCT01597141Not ApplicableCompleted
Psychosis: Early Detection, Intervention and Prevention
Showing all 5 trials